21,878 reports of this reaction
8.2% of all EVOLOCUMAB reports
#3 most reported adverse reaction
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS is the #3 most commonly reported adverse reaction for EVOLOCUMAB, manufactured by Amgen USA Inc.. There are 21,878 FDA adverse event reports linking EVOLOCUMAB to WRONG TECHNIQUE IN PRODUCT USAGE PROCESS. This represents approximately 8.2% of all 266,603 adverse event reports for this drug.
Patients taking EVOLOCUMAB who experience wrong technique in product usage process should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS is moderately reported among EVOLOCUMAB users, representing a notable but not dominant share of adverse events.
In addition to wrong technique in product usage process, the following adverse reactions have been reported for EVOLOCUMAB:
The following drugs have also been linked to wrong technique in product usage process in FDA adverse event reports:
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS has been reported as an adverse event in 21,878 FDA reports for EVOLOCUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS accounts for approximately 8.2% of all adverse event reports for EVOLOCUMAB, making it one of the most commonly reported side effect.
If you experience wrong technique in product usage process while taking EVOLOCUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.